CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-09-20): Hepatitis C drug Incivo (telaprevir) gets EU nod

Regulatory

Hepatitis C drug Incivo (telaprevir) gets EU nod

Last Updated: 2011-09-20 18:55:29 -0400 (Reuters Health)

(Reuters) - Vertex Pharmaceuticals Inc and partner Johnson & Johnson won European approval for their hepatitis C drug telaprevir, Vertex said on Tuesday.

The pill won U.S. approval in May. Known as Incivek in the United States, it will be called Incivo in Europe.

Telaprevir can nearly double the chances of curing hepatitis C compared with prior standard treatments.

Approval for the drug in Europe was expected after the European Medicines Agency recommended it in July.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.